Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Prices $35M Public Stock Offering

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte announced today its public offering of about 9.3 million shares of its common stock at $3.75 per share for gross proceeds of approximately $35 million.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.4 million shares of common stock at the public offering price to cover any overallotments.

Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the comanager for the offering, which should close on or about February 12.   

OncoCyte intends to use the proceeds to support commercialization of it DetermaVu test, a blood-based assay to aid in differentiating benign from cancerous lung nodules when they are discovered either in lung cancer screening programs or incidentally by imaging for an unrelated condition.

Money raised will help the company complete clinical studies to support reimbursement and adoption of the test, and to initiate future product development.